preprints.org > biology and life sciences > immunology and microbiology > doi: 10.20944/preprints202212.0555.v1

Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Version 1 : Received: 27 December 2022 / Approved: 29 December 2022 / Online: 29 December 2022 (06:41:22 CET)

Cutaneous T cell lymphomas (CTCLs) are caused by malignant clonal proliferation of skin-tropic T cells. Most patients have an indolent disease course managed with skin-directed therapies, while some entities, or in advanced stages of disease, have aggressive progression and poor survival. To efficiently treat CTCL consistent entity markers are needed to prevent the delay in diagnosis and to provide disease specific treatment to patients. Recently, the introduction of high throughput parallel sequencing methods resulted in identification of numerous genetic and ep-igenetic alterations affecting the transcriptome of CTCL cells. In this review, most relevant genes, including TOX, CADM1, PLS3, DNM3, CXCL13, PD-1, BCL11B and TMEM244 are reported that are specifically expressed in CTCL. Upon verification their specificity and sensitivity in larger studies, their altered expression will be able to be recognized as novel biomarkers, that can im-prove the early diagnosis of CTCL.

CTCL; biomarker; TOX; PLS3; CADM1; DNM3; CXCL13; PD-1; BCL11B; TMEM244

Biology and Life Sciences, Immunology and Microbiology

* All users must log in before leaving a comment